2019 Novel Coronavirus (COVID-19)



South Dakota Department of Health

November 4, 2021

We will begin in just a few moments. Thanks!

SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

This is an **emerging, rapidly evolving situation**. Information in this presentation is current as of November 3, 2021. Please check the South Dakota Department of Health website for the most current information and guidance.

COVID.sd.gov

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Infection-Induced vs. mRNA Vaccine-Induced Immunity



- During Jan-Sep 2021, the lowest likelihood of infection occurred among those vaccinated rather than those with prior infection
- Findings were robust when accounting for:
  - Time since infection or vaccination
  - Before and during Delta variant
  - mRNA vaccine
  - Age of persons in the study
- Included
  - 1,020 unvaccinated persons with reinfection
  - 6,328 fully vaccinated person with breakthrough infection

https://www.cdc.gov/mmwr/volumes/70/wr/mm7044e1.htm?s_cid=mm7044e1_w

SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

Agenda

- Situation Update
- Laboratory Guidance
- Vaccination Update
- Infection Prevention
- Community Mitigation
- Supply Chain Management
- On-going Communications
- Q&A Session

SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

Coronavirus Situation

- International
  - 246,951,274 confirmed cases
    - 5,004,855 deaths
- United States (50 states + DC)
  - 45,678,478 confirmed cases
    - 740,366 deaths
- South Dakota
  - 155,603 confirmed and probable cases
    - 2,249 deaths
    - 147,841 recovered cases

As of November 2nd, 2021

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Epidemiologic "Epi" Curve of COVID-19 Cases, by Date Reported to SD-DOH



As of November 2nd, 2021

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

COVID-19 Case Map, by County



Community Spread	Number of Counties
Low	2
Moderate	0
Substantial	6
High	58

As of November 2nd, 2021

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

General Testing Recommendations

Medical providers are recommended to test individuals (1) identified as a close contact to a person with COVID-19 or (2) signs and symptoms compatible with COVID-19 infection, including:

- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea

https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html

SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

Reporting COVID-19 Tests to SD-DOH

- **Reminder**: Coronavirus respiratory syndromes are a Category I disease
- Report ***immediately*** on suspicion of disease
- Reporting mechanisms:
  - Electronic Laboratory Report (ELR) – HL7 message to SD Health Link (health information exchange)
  - Flat file (CSV) – Secure email
  - Disease reporting website – sd.gov/diseasereport
    - Ensure patient phone numbers are included
  - Fax – 605.773.5509

SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

Cases, Hospitalizations, and Deaths by Age Group Cumulative



	0-9y	10-19y	20-29y	30-39y	40-49y	50-59y	60-69y	70-79y	80+y
Cases	5.51%	12.21%	17.25%	16.55%	13.98%	13.42%	11.17%	5.89%	4.02%
Hospitalized	0.89%	0.51%	1.41%	2.07%	3.27%	5.34%	9.26%	9.89%	26.26%
Deaths	0%	0%	0.04%	0.13%	0.25%	0.70%	1.91%	5.71%	18.32%

Pct of Cases (distribution of cases across age groups)
Pct Hospitalized (of cases within age groups)
Pct Died (of cases within age groups)

As of November 1st, 2021

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Cases, Hospitalizations, and Deaths by Age Group
June 1st to November 1st, 2021



	0-9y	10-19y	20-29y	30-39y	40-49y	50-59y	60-69y	70-79y	80+y
Cases	9.99%	13.73%	15.58%	16.72%	12.73%	11.31%	10.75%	5.94%	3.25%
Hospitalized	0.92%	0.37%	1.87%	2.65%	4.13%	6.00%	8.27%	14.03%	24.29%
Deaths	0%	0%	0.04%	0.19%	0.22%	0.70%	1.44%	2.56%	5.76%

Pct of Cases (distribution of cases across age groups)
Pct Hospitalized (of cases within age groups)
Pct Died (of cases within age groups)

As of November 1st, 2021

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Breakthrough, Variant, and Reinfection Cases

Breakthrough Cases	#
Cases	5,441
Hospitalized	312
Died	58

Reinfection	#
Cases	1,047
Hospitalized	57
Died	14

Variant Cases	#
Cases	649
Hospitalized	35
Died	9

COVID-19 Variant Data under *Tables* tab:
https://doh.sd.gov/COVID/Dashboard.aspx

As of November 2nd, 2021

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

At least 1 Dose COVID-19 Vaccine, Coverage Rate by Age Group, SD



SOUTH DAKOTA DEPARTMENT OF HEALTH

As of November 2nd, 2021

Not intended for press or for reporting purposes.

COVID-19 Vaccine 3rd Dose/Booster
Coverage Rate by Age Group, Gender, Race and Ethnicity, SD

Total Doses Administered*	Total Persons Administered a Vaccine*	Percent of State Population with at least 1 Dose**
908,338	452,739	68%

Manufacturer	# of Doses
Janssen	31,118
Moderna	359,402
Pfizer	517,818

Doses	# of Recipients
Janssen - Series complete	30,735
Janssen - Booster dose	377
Moderna - 1 dose	14,336
Moderna - Series complete	163,685
Moderna - 3rd dose	17,638
Pfizer - 1 dose	21,888
Pfizer - Series complete	223,944
Pfizer - 3rd/Booster dose	47,917

Doses	% of Pop.
1 dose	67.92%
Booster dose	8.78%
Series Complete	58.29%





Age Range (Years)	3rd/Booster Dose %
<12	0.00%
12-15	0.00%
16-17	0.00%
18-24	0.09%
25-39	0.63%
40-49	0.57%
50-64	1.72%
65-74	3.23%
75+	2.54%
Total	**8.78%**

Race	Hispanic	Non-Hispanic	Unknown	Total
Asian / Pacific Islander		0.01%	0.00%	**0.01%**
Black		0.02%	0.00%	**0.03%**
Hispanic	0.00%	0.00%	0.00%	**0.01%**
Native American		0.05%	0.02%	**0.06%**
Other		0.06%	0.05%	**0.11%**
Unknown		0.04%	0.22%	**0.26%**
White		7.23%	1.08%	**8.30%**
Total	**0.00%**	**7.40%**	**1.37%**	**8.78%**

SOUTH DAKOTA DEPARTMENT OF HEALTH

As of November 2nd, 2021

Not intended for press or for reporting purposes.

Travel Proclamation - CDC Issues Orders Operationalizing the President's Safer, More Stringent International Travel System

These travel requirements will be effective for air travel to the United States from any foreign country at or after 12:01AM ET on November 8, 2021.

- Non-U.S. citizens entering the country will be required to be fully vaccinated and provide proof of their vaccination status.
- Fully vaccinated air passengers will continue to be required to show a negative pre-departure COVID-19 test taken no more than 3 days before they board their flight to the United States.
- Air passengers who are not fully vaccinated will be required to show a negative pre-departure COVID-19 test taken no more than 1 day before they board their flight to the United States.
- All air passengers to the United States will be required to provide basic contact information to airlines before boarding flights to the United States.

https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html

Not intended for press or for reporting purposes.

Effectiveness of Pfizer - BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years - United States, June–September 2021

TABLE 3. Vaccine effectiveness* against COVID-19 among hospitalized patients aged 12–18 years, by vaccination status† — 19 pediatric hospitals, 16 states,§ July–September 2021

Age group, yrs	No. vaccinated/Total (%)		Vaccine effectiveness, % (95% CI)
	Case-patients	Controls	
All	6/179 (3.4)	93/285 (32.6)	93 (83–97)
12–15	4/106 (3.8)	53/179 (29.6)	91 (74–97)
16–18	2/73 (2.7)	40/106 (37.7)	94 (78–99)

Abbreviation: CI = confidence interval.

http://dx.doi.org/10.15585/mmwr.mm7042e1

SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January–August 2021

FIGURE 1. COVID-19–associated monthly hospitalization rates per 100,000 population among adults aged ≥18 years,* by age group, month, and period relative to SARS-CoV-2 B.1.617.2 (Delta) variant predominance† — COVID-NET, 14 states,§ January–August 2021



TABLE. Demographic characteristics and clinical interventions and outcomes among 7,615 nonpregnant adults aged ≥18 years hospitalized with COVID-19,* by vaccination status† and period relative to SARS-CoV-2 B.1.617.2 (Delta) variant predominance§ — COVID-NET, 14 states,¶ January–August 2021

	Weighted % of COVID-19 hospitalizations (95% CI)								
	Total hospitalizations**			Unvaccinated			Fully vaccinated		
Characteristic	Pre-Delta period	Delta period	p-value††	Pre-Delta period	Delta period	p-value††	Pre-Delta period	Delta period	p-value††
Total	5,951	1,664	—	4,896	1,145	—	389	393	—
Demographic characteristics§§									
Age group, yrs									
18–49	24.7 (23.2–26.3)	35.8 (32.1–39.5)	<0.01	26.9 (25.2–28.7)	43.6 (39.1–48.2)	<0.01	10.6 (6.8–15.4)	10.8 (7.1–15.4)	>0.99
50–64	31.2 (29.5–33.0)	30.4 (27.3–33.7)		32.4 (30.5–34.4)	33.6 (29.8–37.6)		17.2 (12.9–22.3)	18.8 (13.6–25.0)	
≥65	44.1 (42.0–46.2)	33.8 (30.4–37.4)		40.6 (38.3–43.0)	22.8 (19.1–26.8)		72.2 (65.8–78.0)	70.4 (63.6–76.7)	

http://dx.doi.org/10.15585/mmwr.mm7043e1

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021

TABLE 3. Adjusted relative risks for mortality of COVID-19 vaccine recipients and unvaccinated comparison groups*— seven integrated health care organizations, United States, December 14, 2020–July 31, 2021

	Vaccine type, aRR, (95% CI)				
	Pfizer-BioNTech		Moderna		Janssen
Characteristic	After dose 1	After dose 2	After dose 1	After dose 2	After dose 1
Overall†	**0.41 (0.38–0.44)**	**0.34 (0.33–0.36)**	**0.34 (0.32–0.37)**	**0.31(0.30–0.33)**	**0.54 (0.49–0.59)**
Age group,§ yrs					
12–17	0.85 (0.38–1.90)	0.73 (0.33–1.64)	NA	NA	NA
18–44	0.37 (0.24–0.57)	0.36 (0.28–0.46)	0.46 (0.31–0.69)	0.38 (0.29–0.50)	0.55 (0.36–0.82)
45–64	0.35 (0.29–0.42)	0.28 (0.25–0.31)	0.31 (0.26–0.37)	0.33 (0.29–0.37)	0.40 (0.34–0.49)
65–74	0.39 (0.33–0.47)				0.50 (0.39–0.63)
75–84	0.38 (0.33–0.46)				0.58 (0.48–0.71)
≥85	0.46 (0.39–0.54)				0.68 (0.56–0.82)
Sex¶					
Male	0.41 (0.37–0.46)				0.52 (0.46–0.60)
Female	0.41 (0.36–0.45)				0.56 (0.49–0.64)
Race/Ethnicity**					
Hispanic	0.36 (0.30–0.42)				0.58 (0.46–0.73)
White, non-Hispanic	0.44 (0.38–0.50)				0.53 (0.46–0.61)
Asian, non-Hispanic	0.31 (0.25–0.39)				0.68 (0.52–0.88)
Black, non-Hispanic	0.38 (0.31–0.47)				0.47 (0.36–0.63)
Multiple races/Other/Unknown	0.46 (0.36–0.60)				0.52 (0.38–0.71)

Abbreviations: aRR = adjusted relative risk; CI = confidence interval; Datalink.

http://dx.doi.org/10.15585/mmwr.mm7043e2

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Selected CDC Updates

Available at: https://www.cdc.gov/coronavirus/2019-ncov/whats-new-all.html

COVID Data Tracker: https://covid.cdc.gov/covid-data-tracker/#datatracker-home

Covid-19 Vaccines for Moderately to Severely Immunocompromised: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html

Travel Recommendations by Destination: https://www.cdc.gov/coronavirus/2019-ncov/travelers/map-and-travel-notices.html

Not intended for press or for reporting purposes.

Laboratory and COVID Therapy Updates

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

COVID-19 Tests Reported to SDDOH by Month



COVID-19 Supply Chain Updates:

- ✓ Abbott ID Now on allocation
- ✓ Abbott BinaxNOW on allocation and difficult to acquire
- ✓ Quidel antigen tests on allocation but available with lead time
- ✓ BD Veritor at-home COVID-19 antigen test recently received FDA-EUA approval

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Changes to Respiratory Disease Testing at SDPHL

- This year, SDPHL will make changes to its respiratory disease testing program during influenza season.
- Changes to the SDPHL testing program support respiratory disease surveillance.
- Surveillance data are used at the local, state, and national levels to influence public health response.

- This year, SDPHL will use the following approaches to respiratory disease testing:
  - Specimens submitted for COVID testing may receive:
    1. COVID Stand-Alone testing: a single COVID RT-PCR test, OR…
    2. COVID+Influenza Testing: a COVID+influenza multiplex RT-PCR test, OR…
    3. Syndromic Testing: a highly multiplexed PCR test
  - Specimen submitted for Influenza testing through the sentinel surveillance program may receive:
    1. COVID+Influenza Testing: a COVID+influenza multiplex RT-PCR test, OR…
    2. Syndromic Testing: in rare cases, a highly multiplexed PCR test

Testing Resources Available through SDDOH

- Specimen collection supplies
  - Nasopharyngeal swabs
  - Nasal swabs
  - Viral transport medium
- Packaging and shipping supplies
  - Category B shippers
    - Box
    - Ice pack
    - Biohazard bag
    - Tyvek bag
- Antigen test kits
  - Abbott BinaxNOW
  - Quidel QuickVue
  - ***These supplies available for DOH-supported testing program; not currently for federally mandated testing***

Item	Quantity Shipped from SDPHL 8/21-10/21
Nasopharyngeal Swabs	32,075
Nasal Swabs	3,391
Viral Transport Medium	35,177
Biohazard Bags	5,957
Tyvek Bags	2,176
Boxes	1,926
Ice Packs	1,564
Abbott BinaxNOW Tests	14,520
Quick Vue Tests	3,375

This call is not intended for the press or for reporting purposes.

Testing Resource Requests

- For questions about DOH antigen testing support, please contact:
  - Long-term Care: Denise.Broadbent@state.sd.us
  - Healthcare: Laurie.Gregg@state.sd.us
  - K-12 Schools: Joe.Moran@state.sd.us
  - Higher Education: Laurie.Gregg@state.sd.us
  - Childcare Providers: Laura.Nordbye@state.sd.us
  - Businesses: Leanne.Nicholls@state.sd.us
  - Homeless Shelters: Program in Development
  - Confinement Facilities: Program in Development

- Inquiries for Abbott BinaxNOW and ID NOW resources can also be sent to: Dorothy.Ahten@abbott.com

- Inquiries for Quidel QuickVue resources can also be sent to: Matt.VanDam@McKesson.com

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

SDPHL SARS-CoV-2 Sequencing: Specimen Requests

- The SDPHL monthly sequencing goal is ~~300~~ 400 specimens.
- SDPHL asks that laboratories send the following SARS-CoV-2-positive specimens each week:
  - Rural clinics, FQHCs, etc: first five (5)
  - Indian Health Services and tribal clinics: first ten (10)
  - Critical access hospital laboratories: first ten (~~10~~ 15)
  - Higher-education partners: first ten (10)
  - Large hospital laboratory partners: first twenty-five (~~25~~ 35)
  - Reference laboratory partners: first twenty-five (~~25~~ 35)
- Nasal or nasopharyngeal swab specimens should be submitted in viral transport medium, sterile saline or sterile PBS within 72 hours of collection.

The SDPHL update in December will highlight the University of Texas Variant Detection Calculator

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

COVID-19 Therapy Availability

- Monoclonal antibodies are now only available by federal allocation through Amerisourcebergen (ASB).
  - Allocation is based on case counts, hospitalizations, and therapy use
  - Monoclonal antibody (mAb) therapies available through ASB include:
    - REGEN-CoV (Regeneron) – intravenous infusion and subcutaneous injection
    - Bamlanivimab/Etesevimab (Ely Lilly) – intravenous infusion only
    - Sotrovimab (GlaxoSmithKline) – intravenous infusion only
  - mAb AZD-7442 (AstraZeneca) will be considered for FDA EUA approval in the next few weeks.
- Molnupiravir (Merck/Ridgeback) will be considered for FDA EUA approval in late November.

This call is not intended for the press or for reporting purposes.

Molnupiravir

- Molnupiravir is an antiviral drug taken orally every 12 hours for 5 days; a treatment course contains 10 doses.
- Molnupiravir significantly reduced the risk of hospitalization and death in a recent trial (MOVe-OUT) involving non-hospitalized adult patient with mild to moderate COVID-19.
- Merck entered into a procurement agreement with USG and upon FDA EUA approval, Merck will provide the USG 1.7 million courses of molnupiravir for approximately $1.2B.
- Merck has also entered into supply and purchase agreements with other governments worldwide.
- Merck has entered into voluntary licensing agreements with generic manufacturers to accelerate availability of molnupiravir in more than 100 low and middle income countries.
- Merck anticipates production of 10 million courses of treatment by the end of 2021 with 20 million more doses expected in 2022.

COVID-19 Monoclonal Antibody Therapy Allocation

Allocation Wk (Date)	REGEN-CoV	Bam/Ete	Sotrovimab	Total Courses
Week 1 (9/13)	380	50	-	430
Week 2 (9/20)	336	156	-	492
Week 3 (9/27)	396	170	-	566
Week 4 (10/4)	360	200	-	560
Week 5 (10/11)	216	260	144	620
Week 6 (10/18)	160	312	78	550
Week 7 (10/25)	200	348	138	686
Week 8 (11/1)	170	288	114	572



- **Monoclonal antibody therapy is not a substitute for vaccination!**
- It is strongly recommended that all eligible individuals receive a COVID-19 vaccine.
- Due to high demand, mAb therapy is only recommended for highest-risk COVID patients.
- Questions about mAb therapies and availability can be sent to: Bob.Coolidge@state.sd.us

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Late Breaking News

- The Occupational Safety and Health Administration (OSHA) released its highly anticipated emergency temporary standard requiring businesses with at least 100 employees to mandate that their employees get vaccinated against the coronavirus or wear a mask and test for COVID-19 on at least a weekly basis.

- Additionally, the White House announced the following details:
  - All unvaccinated workers must begin wearing masks by Dec. 5 and provide a negative COVID-19 test on a weekly basis beginning Jan. 4.
  - The deadline for federal contractors to comply has been pushed back to Jan. 4.
  - Companies are not required to pay for or provide the tests unless they are otherwise required to by state or local laws or in labor union contracts.

- Legal challenge is expected.

Vaccination Update

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Doses Administered

11/03/2021

Total Doses Administered*	Total Persons Administered a Vaccine*	Percent of State Population with at least 1 Dose**
908,338	452,739	68%

Manufacturer	# of Doses
Janssen	31,118
Moderna	359,402
Pfizer	517,818

Doses	# of Recipients
Janssen - Series complete	30,735
Janssen - Booster dose	377
Moderna - 1 dose	14,336
Moderna - Series complete	163,685
Moderna - 3rd/Booster dose	17,638
Pfizer - 1 dose	21,888
Pfizer - Series complete	223,944
Pfizer - 3rd/Booster dose	47,917

Doses	% of Pop.
1 dose	67.92%
Booster dose	8.78%
Series Complete	58.29%

Based on 2019 Census Estimate for those aged 12+ years.

10/13/2021

Total Doses Administered*	Total Persons Administered a Vaccine*	Percent of State Population with at least 1 Dose**
794,822	427,298	65%

Manufacturer	# of Doses
Janssen	28,518
Moderna	319,684
Pfizer	446,620

Doses	# of Recipients
Janssen - Series Complete	28,518
Moderna - 1 dose	11,202
Moderna - Series Complete	154,205
Pfizer - 1 dose	20,681
Pfizer - Series Complete	212,928

Doses	% of Pop.
1 dose	65.00%
Series Complete	59.38%

Based on 2019 Census Estimate for those aged 12+ years.

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

COVID Vaccine coverage by age as of 11/02/2021



Not intended for press or for reporting purposes.

SD DOSES Ordered All Partners



SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

SD DOSES Ordered All Partners

	Federal Entity	Jurisdiction	Pharmacy	Total
Ordered	174,200	805,470	413,210	1,392,880
Shipped	169,400	792,870	404,510	1,366,780
Delivered	169,400	790,560	396,270	1,356,230

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Doses Administered by Dose Number



Doses Administered by Vaccine and Channel





Filter by Date

Not intended for press or for reporting purposes

Moderna and J&J Boosters

The use of a single booster dose of the **Moderna** COVID-19 Vaccine that may be administered at least 6 months after completion of the primary series to individuals:

- 65 years of age and older
- 18 through 64 years of age at high risk of severe COVID-19
- 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2

These groups are the same as the Pfizer booster recommendations.

The use of a single booster dose of the **Janssen (Johnson and Johnson)** COVID-19 Vaccine may be administered at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.

Mixing and Matching COVID-19 Vaccine Boosters

Eligible individuals may choose which vaccine they receive as a booster dose.

- There are no warnings against any combination of vaccine.
- Patients may choose to continue with the vaccine they originally received.

Booster Doses and the Immunocompromised

Moderately and severely immunocompromised people aged ≥18 years who completed an mRNA COVID-19 vaccine primary series and received an additional mRNA vaccine dose **may** receive a single COVID-19 booster dose (Pfizer-BioNTech, Moderna, or Janssen) at least 6 months after completing their third mRNA vaccine dose.

- This guidance allows for a total of 4 vaccinations.

Pfizer Pediatric COVID-19 Vaccine

The CDC Director has endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine.

- CDC now expands vaccine recommendations to about 28 million children in the United States in this age group and allows providers to begin vaccinating them as soon as possible.
- The FDA has already authorized the Pfizer pediatric COVID-19 vaccine for emergency use.
- Pediatric doses are already being administered.

Pfizer Pediatric COVID-19 Vaccine Dosage/Administration

- Adolescents ages 12 years and older receive the same dosage of Pfizer-BioNTech COVID-19 Vaccine as adults.
- Children ages 5 through 11 years receive one-third of the adult dose, not to be confused with injection volume, of Pfizer-BioNTech COVID-19 Vaccine. Smaller needles, designed specifically for children, are used for children ages 5 through11 years.
- COVID-19 vaccine dosage does not vary by patient weight but by age on the day of vaccination.
- Your child will need a second shot of the Pfizer-BioNTech COVID-19 Vaccine three weeks after their first shot.

Pfizer Pediatric COVID-19 Vaccine

Authorized For	Pfizer-BioNTech	Moderna	J&J / Janssen
4 years and under	No	No	No
5–11 years old	**Yes**	No	No
12–17 years old	**Yes**	No	No
18 years and older	**Yes**	**Yes**	**Yes**

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Current and Potential Future Formulations: Product Characteristics

PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL

Description	Current Formulation	Future Formulations	
	Dilute Prior to Use	*Do Not Dilute*	*Dilute Prior to Use*
Age Group	12 years and older	12 years and older	5 to <12 years*
Vial Cap Color	PURPLE 	GRAY 	ORANGE 
Dose	**30 mcg**	**30 mcg**	**10 mcg**
Injection Volume	0.3 mL	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	2.25 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	**NO DILUTION**	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)
Storage Conditions			
ULT Freezer (-90ºC to -60ºC)	9 months	6 months	6 months
Freezer (-25°C to -15°C)	2 weeks	**N/A**	**N/A**
Refrigerator (2°C to 8°C)	1 month	10 weeks	10 weeks

*Diluent: 0.9% Sodium Chloride Injection, USP

SOUTH DAKOTA DEPARTMENT OF HEALTH

Not intended for press or for reporting purposes.

Infection Prevention

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

COVID-19 RESOURCE AND ANNOUNCEMENTS

- **CDC COVID-19 Guidance**: Below is a list of healthcare IPC and other related guidance documents that have been recently published or updated by CDC or CMS. For additional updates, CDC's What's New & Updated tool is a helpful way to stay up-to-date with new and updated content on CDC's COVID-19 webpages. Users can filter by date, webpage type, audience, and topic.
    - Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States (Updated 10/27/21)
    - COVID-19 Vaccine Booster Shots (Updated 10/27/21)
    - Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing (Updated 10/25/21)
    - COVID-19 Vaccines for Long-term Care Residents (Updated 10/21/21)
    - Clinical Questions about COVID-19: Questions and Answers (Updated 10/15/21)

- **COVID-19 Booster Shot Information:** As of 10/28/21 data reported into NHSN shows that close to 20% of nursing home residents have received a booster shot and this number is steadily increasing week by week.

  CDC Resources

  - Media statement: CDC Expands Eligibility for COVID-19 Booster Shots
  - Updated booster shot webpage for the public
  - Updated Clinical Considerations

  Moderna also issued a letter for healthcare providers regarding booster dosing. **Please note for Moderna, providers cannot puncture the vial stopper more than 20 times.** That means that you can get a maximum of 20 doses out of each vial.

SOUTH DAKOTA
Foundation for Medical Care

South Dakota Project Firstline is LIVE! Check Out the Website:

https://www.sdprojectfirstline.org

*Training modules
*Videos
*Brochures and printouts
*Contact information for training opportunities for your facility

Additional infection control topics and videos can be found at:
https://www.cdc.gov/infectioncontrol/projectfirstline/index.html

Not intended for press or for reporting purposes

SOUTH DAKOTA DEPARTMENT OF HEALTH

Infection Control Questions? Contact Us:

Kipp Stahl kipp.stahl@state.sd.us
Leah Bomesberger leah.bomesberger@state.sd.us

Not intended for press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Community Mitigation

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Dashboard

SD Overview | Demographics | Trends | Hospital Capacity | Hospitalized & ILI | Tables | Vaccines | Deaths

New Confirmed Cases	New Probable Cases	Active Cases	Recovered Cases	Currently Hospitalized
372	148	5,662	148,208	187

Community Spread Map by County of Residence



Community Spread Low Moderate Substantial High

Hover over a county to see its details, or click county to update the orange boxes.

Total Confirmed Cases	Total Probable Cases	PCR Test Positivity Rate, Last 7 Days	Total Tests
134,600	21,523	13.4% (10/26/2021 - 11/1/2021)	1,618,390

Ever Hospitalized	Deaths Among Cases	% Progress (September Goal: 44233 Te...	% Progress (October Goal: 44233 Tests)	% Progress (November Goal: 44233 Tests)
7,909	2,253	303%	233%	13%

SD Overview | Demographics | Trends | Hospital Capacity | Hospitalized & ILI | Tables | Vaccines | Deaths

County

All

PCR Test Positivity Rate, Last 7 Days	PCR Test Positivity Rate, Last 14 Days	PCR Test Positivity Rate, Cumulative
13.4% (10/26/2021 - 11/1/2021)	13.2% (10/19/2021 - 11/1/2021)	13.2% (3/10/2020 - 11/1/2021)

PCR Test Positivity Rate: *This rate is equal to the number of positive PCR tests divided by total PCR tests, within the specified period of time. Date range includes last full day (24 hours) captured in the data set.*

Confirmed Cases and 14-Day Trend Line by Date Reported to SD-DOH



14-Day Trend of Confirmed Cases by Date Reported to SD-DOH: *This graph shows the trend (increasing or decreasing) of COVID-19 confirmed cases (persons who meet the national surveillance case definition case for COVID-19) at the state or county level.*

Daily Rate of Total Cases, Last 7 Days	Rate of Total Cases, Cumulative
10/26/2021 - 11/1/2021	3/10/2020 - 11/1/2021
36.98	17,668
Daily Case Rate per Capita	Case Rate per Capita

SOUTH DAKOTA DEPARTMENT OF HEALTH

This call is not intended for the press or for reporting purposes.

Supply Chain Management

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

PPE Request Procedure

All requests for PPE from DOH must be:

- Emailed to COVIDResourceRequests@state.sd.us,
- Faxed to **605.773.5942,** or
- Called in to **605.773.3048** to ensure prioritization and coordination of requests.

- Do not duplicate your request by using all three means of communication.

- Any requests received through any other email or number will all be directed to email COVIDResourceRequests@state.sd.us OR call **605.773.3048** and requesting entities must provide information regarding their current facility status.

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

On-going Communication

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Helpful sources of information:

covid.sd.gov

coronavirus.gov

- **SD COVID-19 Help Line: 800-997-2880**

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Communications

- SD-HAN: sdhan.sd.gov
- Epi Listserv
- Lab Listserv
- HAI Listserv
- OLC Listserv

Visit **covid.sd.gov** to subscribe

This call is not intended for the press or for reporting purposes.

SOUTH DAKOTA DEPARTMENT OF HEALTH

Questions?

Follow-up after the webinar

COVID Helpline: 800-997-2880
Epidemiology: 605-773-3737
Laboratory: 605-773-3368

COVID.sd.gov
COVIDSD@state.sd.us

Not intended for press or for reporting purposes

SOUTH DAKOTA DEPARTMENT OF HEALTH